For the quarter ending 2025-09-30, SBFM had -$770,560 decrease in cash & cash equivalents over the period. -$735,840 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash and cash equivalents at beginning of period | 9,686,529 | - |
| Net (loss) | -883,820 | -2,950,605 |
| Depreciation and amortization | 96,163 | 137,326 |
| Intangible asset impairment | 554,650 | 1,061,809 |
| Stock issued for services | 0 | 0 |
| Accounts receivable | 649,850 | -492,384 |
| Inventory | 1,286,164 | 1,123,909 |
| Prepaid expenses | -36,168 | -255,548 |
| Reduction in right-of-use asset | -147,016 | - |
| Accounts payable & accrued expenses | 1,224,786 | -849,702 |
| Lease liability | -129,741 | - |
| Earn-out payable | 0 | 0 |
| Income tax payable | 162,992 | -10,118 |
| Net cash flows (used in) operating activities | -727,800 | -2,987,267 |
| Purchase of intangible assets | 26,103 | 594,714 |
| Purchase of equipment | 8,040 | 167,490 |
| Reduction in right-of-use asset | - | -94,402 |
| Asset disposition | 10,250 | - |
| Net cash flows (used in) investing activities | -118,295 | -667,802 |
| Proceeds from public offering net (common stock) | 0 | 1,828,596 |
| Exercise of warrants | 0 | 2,195,312 |
| Purchase of treasury stock | 0 | 0 |
| Lease liability | - | 75,536 |
| Net cash flows provided by financing activities | 75,536 | 3,948,372 |
| Net increase (decrease) in cash and cash equivalents | -770,560 | 293,304 |
| Effect of exchange rate changes on cash | 97,165 | - |
| Cash and cash equivalents at end of period | 9,306,438 | - |
Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc. (SBFM)